©The Author(s) 2025.
World J Virol. Sep 25, 2025; 14(3): 108405
Published online Sep 25, 2025. doi: 10.5501/wjv.v14.i3.108405
Published online Sep 25, 2025. doi: 10.5501/wjv.v14.i3.108405
Table 6 Comparative overview of Marburg, Ebola and Lassa viruses
| Feature | MARV | EBOV | Lassa virus |
| Virus family | Filoviridae | Filoviridae | Arenaviridae |
| First identified outbreak | 1967: Marburg and Frankfurt, Germany and Belgrade, Serbia | 1976: Yambuku, Democratic Republic of the Congo and Nzara, Sudan | 1969: Lassa, Nigeria |
| Origin of outbreaks | African green monkeys imported from Uganda | Suspected zoonotic transmission with bats as reservoirs and transmission to humans or other primates | Contact with Mastomys natalensis rodents |
| Reservoir hosts | Egyptian fruit bat (Rousettus aegyptiacus) suspected | Fruit bats (Pteropodidae family), particularly Eidolon helvum | Multimammate rats (Mastomys natalensis) |
| Case fatality rate | 24%-90%, depending on outbreak and case management | 25%-90%, depending on outbreak and case management | 1% overall; up to 15%-20% in hospitalized patients; higher in pregnant females |
| Geographic distribution | Primarily sub-Saharan Africa | Primarily sub-Saharan Africa | West Africa: Nigeria, Sierra Leone, Liberia, Guinea, others |
| Symptoms | Hemorrhagic fever, severe malaise, high fever, vomiting, diarrhea, organ dysfunction | Similar to MARV: Hemorrhagic fever, malaise, vomiting, diarrhea, multiorgan failure | Fever, sore throat, vomiting, bleeding, neurological complications |
| Transmission | Direct contact with bodily fluids (e.g., blood, saliva, urine) of infected persons or animals | Direct contact with bodily fluids of infected persons or animals, contaminated surfaces | Exposure to rodent excreta; human-to-human via body fluids |
| Laboratory diagnosis | PCR, ELISA, virus isolation | PCR, ELISA, virus isolation | PCR, ELISA (IgM, IgG), virus isolation |
| Vaccines | No approved vaccine (research ongoing) | Approved vaccines available (e.g., recombinant vesicular stomatitis virus-ZEBOV for Zaire strain) | No approved vaccine (clinical trials ongoing) |
| Notable outbreaks | Angola (2004-2005), Democratic Republic of the Congo (1998-2000) | West Africa (2014-2016), Democratic Republic of the Congo (multiple outbreaks) | Nigeria (multiple outbreaks annually), Sierra Leone epidemics |
- Citation: Uppala PK, Karanam SK, Kandra NV, Edhi S. Lassa fever: A comprehensive review of virology, clinical management, and global health implications. World J Virol 2025; 14(3): 108405
- URL: https://www.wjgnet.com/2220-3249/full/v14/i3/108405.htm
- DOI: https://dx.doi.org/10.5501/wjv.v14.i3.108405